Home / Business and Economy / BioCryst Acquires Astria, Analysts Adjust Price Target
BioCryst Acquires Astria, Analysts Adjust Price Target
13 Nov
Summary
- Analysts lower BioCryst's fair value estimate to $19.73 per share
- Acquisition of Astria Therapeutics expected to impact revenue growth and synergies
- Analysts remain bullish on BioCryst's commercial leadership and pipeline
On November 13, 2025, BioCryst Pharmaceuticals' stock narrative has shifted as analysts adjust their fair value estimate for the company's shares. The analysts have lowered their price target from $20.27 to $19.73 per share, reflecting the impact of BioCryst's recent acquisition of Astria Therapeutics.
The modest decrease in the price target comes as analysts revise their expectations for BioCryst's revenue growth and projected synergies following the Astria acquisition. Despite this adjustment, the overall outlook for the company remains positive, with analysts highlighting BioCryst's commercial leadership and its strengthened position in the hereditary angioedema (HAE) treatment market.
Several leading Wall Street analysts have provided their perspectives on the acquisition and its implications for BioCryst's future. Cantor Fitzgerald, for instance, has characterized the deal as a "terrific" value, even before anticipated cost synergies, while Citizens JMP believes the addition of Astria's long-acting HAE candidate could "supercharge" BioCryst's earnings growth. TD Cowen has also reinstated coverage with a Buy rating, citing high interest in Astria's Phase 3 trial and confidence in its de-risked profile.
